幽门螺杆菌感染的诊断与临床管理更新
本文综述幽门螺杆菌的流行病学与微生物学,重点讨论非侵入性和侵入性诊断方法的优劣,以及分子方法直接从粪便或组织活检预测克拉霉素耐药的进展。治疗需考虑抗菌药物耐药模式,四联疗法和非克拉霉素三联疗法成功率较高,新型伏诺拉生方案根除率有前景。
要点
- 粪便抗原、尿素呼气试验和组织免疫组化是幽门螺杆菌主要检测手段。
- 培养加表型药敏是耐药检测金标准,但耗时且劳动密集。
- 核酸扩增直接检测及分子耐药标志物是准确替代但未广泛采用。
核心结论
- 幽门螺杆菌感染增加消化性溃疡和胃癌风险,诊断与治疗需结合耐药模式。
- 分子方法可直接从粪便或组织活检诊断并预测克拉霉素耐药。
- 四联疗法和非克拉霉素三联疗法成功率较高,伏诺拉生方案根除率有前景。
研究设计与样本
- 综述,总结幽门螺杆菌的患病率、微生物学、诊断方法与临床管理策略。
主要发现
- 幽门螺杆菌影响全球近半数人口,发展中国家发病率和患病率高。
- 培养后表型药敏是耐药检测金标准,但方法耗时且劳动密集。
- 抗菌药物耐药率因广泛使用抗生素而上升。
关键数值与推荐
- 粪便抗原检测、尿素呼气试验和组织活检免疫组化是主要检测方法。
- 快速核酸扩增检测直接标本及分子耐药标志物是准确替代方法。
- 四联疗法和非克拉霉素三联疗法成功率较高,伏诺拉生方案根除率有前景。
临床怎么用
- 诊断可选用粪便抗原、尿素呼气试验或组织免疫组化。
- 耐药检测以培养加表型药敏为金标准,分子检测可作为准确替代。
- 治疗应参考抗菌药物耐药模式,优先考虑四联或非克拉霉素三联疗法。
局限性
- 培养方法耗时且劳动密集。
- 分子检测方法尚未广泛采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Helicobacter pylori (H. pylori) affects nearly half of the world's populations with high incidence and prevalence rates in developing countries. Infection with H. pylori increases the risk of developing peptic ulcer disease and gastric cancer. This review provides a summary of the prevalence and microbiology of H. pylori with emphasis on the current diagnostic methods and clinical management strategies. CONTENT: This review discusses current options and developments in H. pylori diagnosis with the challenges and advantages associated with both noninvasive and invasive methods. The advantages of molecular methods for the diagnosis of H. pylori infection and prediction of clarithromycin resistance directly from stool or tissue biopsies are discussed. In addition, we provide a brief review on the treatment for H. pylori indicated in patients with evidence of active infection with the organism's antimicrobial resistance patterns taken into consideration. SUMMARY: Testing for H. pylori has largely centered around fecal antigen testing, urea breath testing, and immunohistochemical staining from tissue biopsies. Culture-based diagnostics followed by phenotypic antimicrobial susceptibility testing is the gold standard for detection of resistance patterns. Due to the fastidious nature of the organism, culture methods are time consuming and labor intensive. Rapid nucleic acid amplification tests for H. pylori identification from direct specimens and molecular determination of drug resistance markers are accurate alternatives for H. pylori diagnosis but are not widely adopted. H. pylori antimicrobial resistance rates are on the rise due to the widespread use of antibiotics. Antibiotic regimens including the quadruple therapy and non-clarithromycin triple therapies have a higher success rate, with newer vonoprazon-based regimens showing promising eradication rates.
引用
- Shakir SM, Shakir FA, Couturier MR, et al. Updates to the Diagnosis and Clinical Management of Helicobacter pylori Infections. Clin Chem. 2023. PMID: 37473423. doi:10.1093/clinchem/hvad081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。